University of Maryland Greenebaum Cancer Center Support Grant

Summary

Principal Investigator: Kevin J Cullen
Abstract: DESCRIPTION (provided by applicant): Our strategy at the University of Maryland Marlene and Stewart Greenebaum Cancer Center (UMGCC) is to take advantage of discoveries in basic cancer biology, in conjunction with clinical research to: (1) develop and apply innovative therapeutic and preventive strategies to cancer patients;(2) describe the molecular mechanisms involving specific clinical phenotypes and behaviors;and (3) apply discoveries and strategies to the Maryland community, with the specific focus on cancer disparities. In this application, UMGCC seeks its first competitive renewal of the successful Cancer Center Support Grant (CCSG) application that was awarded in August 2008, in the present application, UMGCC is represented by 215 members working in five full and one developing research programs with 10 full and 3 developing shared services. UMGCC provides an effective umbrella supporting the multidisciplinary cancer research activities of this talented group of investigators. Total cancer funding rose from $47.1 million in 2007 to $62.0 million in 2009. NCI funding in that time increased from $14.4 million to $25.7 million. Supplements will push total cancer funding above $80 million in 2010. In FY2009, UMGCC served almost 2,300 new cancer patients and handled 43,547 outpatient visits, 32,405 infusion visits, and 1,327 inpatient admissions. During FY2009, 1,198 patients participated in over 200 clinical trials. Remarkably, 33 percent of clinical trial participants in FY2009 were underrepresented minorities, reflecting UMGCC's unique position and mission to involve the minority community in state-of-the-art clinical/translational research. UMGCC researchers have made outstanding contributions to our understanding of cancer biology, and important recent work from our laboratories and clinics is now the standard of care worldwide. A 2010 nationwide ranking of U.S. cancer programs placed UMGCC 21st out of more than 900 cancer programs and 18th among NCI-designated centers. Reflecting our remarkable and continued growth, UMGCC seeks to renew its CCSG to enhance and expand its efforts in high-quality and clinically relevant cancer research.
Funding Period: 2008-08-08 - 2016-07-31
more information: NIH RePORT

Top Publications

  1. pmc Management and outcome of stage 3 neuroblastoma
    Shakeel Modak
    Department of Paediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Eur J Cancer 45:90-8. 2009
  2. pmc Common and complex Notch1 mutations in Chinese oral squamous cell carcinoma
    Xiaomeng Song
    Authors Affiliations Department of Oral and Maxillofacial Surgery, Ninth People s Hospital, Shanghai Jiao Tong University School of Medicine Shanghai Key Laboratory of Stomatology, Shanghai, China Department of Oncology and Diagnostic Sciences, University of Maryland School of Dentistry Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore and Personal Diagnostix Inc, Gaithersburg, Maryland
    Clin Cancer Res 20:701-10. 2014
  3. pmc Pim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplication
    Karthika Natarajan
    Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States of America
    PLoS ONE 8:e74653. 2013
  4. pmc The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions
    Jasjeet Bhullar
    Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States of America
    PLoS ONE 8:e71266. 2013
  5. pmc Anti-HDGF targets cancer and cancer stromal stem cells resistant to chemotherapy
    Jun Zhao
    Department of Oncology and Diagnostic Sciences, University of Maryland School of Dentistry, Baltimore, MD 21201, USA
    Clin Cancer Res 19:3567-76. 2013
  6. ncbi Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia
    Ivana Gojo
    University of Maryland Marlene and Stewart Greenebaum Cancer Center UMGCC, Baltimore, MD 21201, USA
    Clin Cancer Res 19:1838-51. 2013
  7. pmc A simple high-throughput technology enables gain-of-function screening of human microRNAs
    Wen Chih Cheng
    Center for Stem Cell Biology and Regenerative Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
    Biotechniques 54:77-86. 2013
  8. pmc The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms
    Karthika Natarajan
    University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA
    Biochem Pharmacol 85:514-24. 2013
  9. pmc Regulatory subunit myristoylation antagonizes calcineurin phosphatase activation in yeast
    Sean Connolly
    Department of Physiology, Program in Oncology, Marlene and Stewart Greenbaum Cancer Center, The University of Maryland Baltimore School of Medicine, Baltimore, Maryland 21201, USA
    J Biol Chem 287:39361-8. 2012
  10. pmc The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2
    Rupashree Sen
    University of Maryland Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Mol Cancer Ther 11:2033-44. 2012

Research Grants

  1. UNMC EPPLEY CANCER CENTER SUPPORT GRANT
    Kenneth H Cowan; Fiscal Year: 2013

Detail Information

Publications17

  1. pmc Management and outcome of stage 3 neuroblastoma
    Shakeel Modak
    Department of Paediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Eur J Cancer 45:90-8. 2009
    ..We describe a single centre approach at Memorial Sloan-Kettering Cancer Centre (MSKCC) from 1991 to 2007 that minimises therapy except for those patients with MYCN-amplified NB...
  2. pmc Common and complex Notch1 mutations in Chinese oral squamous cell carcinoma
    Xiaomeng Song
    Authors Affiliations Department of Oral and Maxillofacial Surgery, Ninth People s Hospital, Shanghai Jiao Tong University School of Medicine Shanghai Key Laboratory of Stomatology, Shanghai, China Department of Oncology and Diagnostic Sciences, University of Maryland School of Dentistry Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore and Personal Diagnostix Inc, Gaithersburg, Maryland
    Clin Cancer Res 20:701-10. 2014
    ..To determine Notch1 mutation status in oral squamous cell carcinoma (OSCC) from Chinese population and its potential clinical implications...
  3. pmc Pim-1 kinase phosphorylates and stabilizes 130 kDa FLT3 and promotes aberrant STAT5 signaling in acute myeloid leukemia with FLT3 internal tandem duplication
    Karthika Natarajan
    Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States of America
    PLoS ONE 8:e74653. 2013
    ..This is, to our knowledge, the first demonstration of a role of Pim-1 in a positive feedback loop promoting aberrant signaling in malignant cells. ..
  4. pmc The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions
    Jasjeet Bhullar
    Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States of America
    PLoS ONE 8:e71266. 2013
    ..These interactions should be considered in the design of treatment regimens combining quizartinib and chemotherapy drugs and in choice of concomitant medications to be administered with quizartinib...
  5. pmc Anti-HDGF targets cancer and cancer stromal stem cells resistant to chemotherapy
    Jun Zhao
    Department of Oncology and Diagnostic Sciences, University of Maryland School of Dentistry, Baltimore, MD 21201, USA
    Clin Cancer Res 19:3567-76. 2013
    ..The remainder will progress during initial treatment (primary resistance). In this study, we test whether the treatment can be improved by inhibiting hepatoma-derived growth factor (HDGF)...
  6. ncbi Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia
    Ivana Gojo
    University of Maryland Marlene and Stewart Greenebaum Cancer Center UMGCC, Baltimore, MD 21201, USA
    Clin Cancer Res 19:1838-51. 2013
    ....
  7. pmc A simple high-throughput technology enables gain-of-function screening of human microRNAs
    Wen Chih Cheng
    Center for Stem Cell Biology and Regenerative Medicine, University of Maryland School of Medicine, Baltimore, MD, USA
    Biotechniques 54:77-86. 2013
    ..Thus, this novel lentiviral library- and qPCR-based miR-HTS technology provides a sensitive platform for functional screening that is straightforward and relatively inexpensive...
  8. pmc The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and -independent mechanisms
    Karthika Natarajan
    University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA
    Biochem Pharmacol 85:514-24. 2013
    ..Decrease in ABCB1 and ABCG2 cell surface expression mediated by Pim-1 inhibition represents a novel mechanism of chemosensitization...
  9. pmc Regulatory subunit myristoylation antagonizes calcineurin phosphatase activation in yeast
    Sean Connolly
    Department of Physiology, Program in Oncology, Marlene and Stewart Greenbaum Cancer Center, The University of Maryland Baltimore School of Medicine, Baltimore, Maryland 21201, USA
    J Biol Chem 287:39361-8. 2012
    ..Our findings are the first demonstration of a functional role for CNB myristoylation and reveal the importance of Nmt1 in modulating cellular calcineurin activation...
  10. pmc The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2
    Rupashree Sen
    University of Maryland Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Mol Cancer Ther 11:2033-44. 2012
    ..Combinations of ponatinib and chemotherapy drugs warrant further testing...
  11. ncbi Quantitative proteomic analysis of mitochondrial proteins reveals prosurvival mechanisms in the perpetuation of radiation-induced genomic instability
    Stefani N Thomas
    Radiation Oncology Research Laboratory, Department of Radiation Oncology, University of Maryland Baltimore, MD 21201, USA
    Free Radic Biol Med 53:618-28. 2012
    ..These data suggest that LS12 cells have adapted mechanisms that allow survival under suboptimal conditions of oxidative stress and compromised mitochondrial function to perpetuate genomic instability...
  12. pmc IsoQuant: a software tool for stable isotope labeling by amino acids in cell culture-based mass spectrometry quantitation
    Zhongping Liao
    Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland 21201, United States
    Anal Chem 84:4535-43. 2012
    ..NET framework version 4.0 and has been tested to be compatible with both 32-bit and 64-bit Windows 7. It is freely available to noncommercial users at http://www.proteomeumb.org/MZw.html ...
  13. pmc Role of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistance
    Karthika Natarajan
    University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA
    Biochem Pharmacol 83:1084-103. 2012
    ..Along with other factors, these transporters may contribute to the inherent resistance of these neoplasms and their failure to be cured...
  14. ncbi Risk assessment in human immunodeficiency virus-associated acute myeloid leukemia
    Michael W Evans
    University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA
    Leuk Lymphoma 53:660-4. 2012
    ..Thus, CD4 count is a strong predictor of short survival in HIV-AML patients regardless of karyotype. Studies evaluating innovative strategies for infection prophylaxis and for improving immune reconstitution are needed...
  15. pmc GRIM-19 disrupts E6/E6AP complex to rescue p53 and induce apoptosis in cervical cancers
    Ying Zhou
    Department of Obstetrics and Gynecology, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, Anhui, The People s Republic of China
    PLoS ONE 6:e22065. 2011
    ..The aims of this study were to determine the potential role of GRIM-19 in rescuing p53 protein and inducing cervical cancer cell apoptosis...
  16. ncbi Neuroblastoma: Therapeutic strategies for a clinical enigma
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, United States
    Cancer Treat Rev 36:307-17. 2010
    ..It is likely that a combination of therapeutic modalities will be required to improve survival and cure rates...
  17. pmc Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms
    Ting Bao
    University of Maryland Greenebaum Cancer Center, Baltimore, Maryland
    Cancer 120:381-9. 2014
    ..The objective of this study was to assess whether real acupuncture (RA), compared with sham acupuncture (SA), improves PROs in patients with breast cancer who are receiving an adjuvant AI...

Research Grants31

  1. UNMC EPPLEY CANCER CENTER SUPPORT GRANT
    Kenneth H Cowan; Fiscal Year: 2013
    ....